OCUL vs MSFT: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

MSFT has stronger fundamentals based on our AI analysis.

OCUL
OCULAR THERAPEUTIX, INC
SELL
72%
Confidence
VS
MSFT
MICROSOFT CORP
BUY
91%
Confidence

OCUL vs MSFT Fundamental Comparison

Metric OCUL MSFT
Revenue $52.0M $158.9B
Net Income $-265.9M $66.2B
Net Margin -511.9% 41.7%
ROE -40.6% 16.9%
ROA -32.9% 10.0%
Current Ratio 15.39x 1.39x
Debt/Equity 0.04x 0.10x
EPS $-1.42 $8.87

Green = Better metric | Red = Weaker metric

View Full OCUL Analysis →
View Full MSFT Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

OCUL vs AAPL MSFT vs GOOGL OCUL vs AMZN MSFT vs NVDA

OCUL vs MSFT: Frequently Asked Questions

Is OCUL or MSFT a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. OCUL is rated SELL (72% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.

How does OCUL compare to MSFT fundamentally?

OCULAR THERAPEUTIX, INC has ROE of -40.6% vs MICROSOFT CORP's 16.9%. Net margins are -511.9% vs 41.7% respectively.

Which stock pays higher dividends, OCUL or MSFT?

OCUL has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in OCUL or MSFT for long term?

For long-term investing, consider that OCUL has SELL rating with 72% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about OCUL vs MSFT?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For OCUL vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.